About admin

This author has not yet filled in any details.
So far admin has created 524 blog entries.

Release Annual Report 2016

Click to download the Pharming Annual Report 2016

PHARM: 4Q16 Recap – Momentum Building into 2017

ROTH – PHARM: 4Q16 Recap - Momentum Building into 2017 Biotech company Pharming Group NV announces the analyst report completed by Scott R. Henry from Roth Capital Partners is published. PHARM: 4Q16 Recap - Momentum Building into 2017 Roth note 10 March 2017 Visit our Analyst Coverage & Reports page to read more reports by ROTH [...]

STIFEL: Pharming Group N.V. (PHARM.NA, Buy) – FY16 results demonstrate benefit of regaining Ruconest

A new analyst report from Stifel Financial Corp. is published. Stifel note 09 March 2017 Visit our Analyst Coverage & Reports page to read more reports from Stifel Financial Corp. Contact Sijmen de Vries, CEO: T: +31 (0)71 524 7400 “This update is for informational purposes only and is not viewed by Pharming to be of a [...]

Pharming publiceert financiële resultaten over 2016

Leiden, 9 maart 2017: Pharming Group N.V. (“Pharming” of “De Onderneming”) (Euronext Amsterdam: PHARM) maakt de (niet-gecontroleerde) financiële resultaten over het boekjaar eindigend op 31 december 2016 bekend. Pharming organiseert vandaag om 09:30 uur (CET) een conference call waarin CEO Sijmen de Vries en CFO Robin Wright de jaarcijfers van Pharming zullen toelichten. Inbelnummer: +31 [...]

Pharming Group Report on Preliminary Financial Results for 2016

Leiden, The Netherlands, 9 March 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the full year ended 31 December 2016. Operational highlights Re-acquisition of all commercial rights to sell RUCONEST® in North America from Valeant in December 2016 in a deal valued at $125 million Positive [...]

Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page

Van Leeuwhoeck issues research note on Pharming (PHARM.AS): Turning the page. Click here to download this analyst report.  Summary: Pharming Group is a Dutch based biopharmaceutical company and one of the oldest publicly traded biotech companies in Europe. The company is focused on the development of recombinant proteins for therapeutic use. Pharming’s main platform is [...]

Pharming meldt additionele conversies van aflosbare converteerbare obligaties

Conversies resulteren in nieuwe uitgifte van 7.558.479 gewone aandelen volgend op eerdere conversies eind januari Totaalbedrag aan uitstaande aflosbare converteerbare obligaties afgenomen van €45 miljoen naar €39,7 miljoen Geen betaling in contanten benodigd voor eerste aflossingstermijn, terwijl ook de tweede termijn hiermee nagenoeg is voldaan Leiden, 3 februari 2017: Pharming Group N.V. (“Pharming” of “de [...]

Pharming announces additional conversions of its Amortizing Bonds

Total number of shares issued in the conversions is 7,558,479 ordinary shares Amount of Amortizing Bonds outstanding is reduced from €45.0 million to €39.7 million No cash payment was required in respect of the first instalment of the Bonds due on 1 February 2017 and the second installment due on 1 March 2017 has now [...]

STIFEL: Pharming Group N.V. (PHARM.NA, Buy) – New stock issue lowers Amortising Bond outstanding

A new analyst report from Stifel Financial Corp. is published. Stifel note 26 January 2017 Visit our Analyst Coverage & Reports page to read more reports from Stifel Financial Corp. Contact Sijmen de Vries, CEO: T: +31 (0)71 524 7400 “This update is for informational purposes only and is not viewed by Pharming to be of a [...]

Pharming meldt uitgifte van nieuwe aandelen door conversie van aflosbare converteerbare obligaties

Aantal uitgegeven aandelen bedraagt 10.823.881 Totaalbedrag aan uitstaande aflosbare converteerbare obligaties neemt af van €45 miljoen naar €41,9 miljoen Leiden, 26 januari 2017: Pharming Group N.V. (“Pharming” of “de Onderneming”) (EURONEXT: PHARM) maakt bekend dat het 10.823.881 nieuwe aandelen heeft uitgegeven aan houders van de aflosbare obligatielening 2017/18, en die een aantal van hun Obligaties [...]